Rationale and Design of the Phase III KEYLYNK-012 Study of Pembrolizumab and Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Stage III Non-Small-Cell Lung Cancer
Titel:
Rationale and Design of the Phase III KEYLYNK-012 Study of Pembrolizumab and Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Stage III Non-Small-Cell Lung Cancer
Auteur:
Jabbour, Salma K. Cho, Byoung Chul Bria, Emilio Kato, Terufumi Bhosle, Jaishree Gainor, Justin F. Reguart, Noemi Wang, Luhua Morgensztern, Daniel Shentu, Yue Kim, Sung Jin Souza, Fabricio Reck, Martin